Patent · US Active

Anti-PCSK9-GLP-1 fusions and methods for use

US10077319B2 · kind B2 · utility

2Cited by
0References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 20, 2015
Grant dateSep 18, 2018
Priority date—
Expiry dateFeb 20, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This application provides anti-PCSK9˜GLP-1 fusions and methods for use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.